OmniComm Systems Celebrates 10 Years of European Headquarters
FORT LAUDERDALE, FL, July 27, 2017 (GLOBE NEWSWIRE) - OmniComm Systems, Inc., a global provider of clinical data management technology, announced the 10-year anniversary of OmniComm Europe GmbH, the European headquarters of the parent company.
Earlier this year, OmniComm Systems-launched in Florida during early 1997-celebrated 20 years of growth and innovation. The company has gained a greater foothold in Europe and Asia in recent years, comprising approximately 20% of its annual revenue, in large part due to the local support from its European headquarters and additional European and Asian offices.
From its launch in July 2007, OmniComm Europe GmbH has grown from a staff of two people in Bonn, Germany to a team of 18 with more than 210 years of combined industry experience. The European headquarters offer expertise in clinical operations, EDC trial build, quality assurance, development, customized solutions, and a multi-lingual helpdesk and training services. OmniComm has additional European offices in the United Kingdom, The Netherlands, and Spain.
“We are very excited about our 10-year track record of organic growth and continuous expansion of our market presence in the region,” said Yvonne Rollinger, Ph.D., managing director of OmniComm Europe GmbH. “We have achieved this milestone through the hard work of our team of industry professionals, who are passionate about delivering exceptional service and support. Seeing the trustful and long-lasting relationships with our clients and partners is a moment of pride and satisfaction for the entire team.”
OmniComm Europe GmbH mainly serves European clients, but also U.S.- and Asia-based trials with international investigative sites. Clients include biopharma and medical device companies, CROs, and academic medical centers.
“We are extremely pleased with the recent success we’ve had across all of our product lines internationally,” said Stephen Johnson, president and CEO of OmniComm Systems. “We’ve experienced a steady 25% compound annual growth rate (CAGR) over the last 10 years. Sales in Europe have doubled in the last two years alone.”
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KVanderPost@omnicomm.com
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
